Newstrail.com

Artificial Intelligence (AI) in Drug Discovery Market will Expand by 30.3% Yearly during 2020–2026 to Reach $2.57 Billion

Artificial Intelligence (AI) in Drug Discovery Market

Despite the COVID-19 effect, the global artificial intelligence (AI) in drug discovery market will expand by 30.3% yearly during 2020–2026 to reach $2.57 billion.

This 178-page report, titled “Global Artificial Intelligence (AI) in Drug Discovery Market 2020-2026 by Offering, Technology, Drug Type, Therapeutic Area, Application, End User, and Region: Trend Forecast and Growth Opportunity,” is highlighted by 86 tables and 86 figures and is based on extensive research of the entire global AI in drug discovery market and all of its sub-segments. Premium primary and secondary information sources are used to create in-depth research and evaluation, with input coming from business specialists working throughout the value chain.

The research offers historical market information for the years 2015 through 2019, revenue projections through 2020, and predictions through 2026. (Please note that the report will be updated before to delivery to ensure that the forecast includes at least 5 years beyond the base year and the most recent historical year serves as the base year.)

The following elements are identified and examined in-depth qualitative analyses:

Porter’s Five Forces: Market Structure, Growth Drivers, Obstacles and Challenges, Emerging Product Trends and Artificial Intelligence (AI) in Drug Discovery Market Opportunities

By taking COVID-19 into consideration, the trend and prognosis for the global market are predicted with an upbeat, fair-minded, and cautious viewpoint. The worldwide AI in drug discovery market is quantified from all angles, including offering, technology, drug type, therapeutic area, application, end user, and region, using the balanced (most likely) projection.

Request Research Sample with Latest Industry Insights (178+ Pages Report): https://altusmarketresearch.com/reports/sample/3536

The worldwide market is divided into the following sub-markets based on offering, with yearly revenue for each part from 2015 to 2026 (historical and projected).

• Service; software

The worldwide Artificial Intelligence (AI) in Drug Discovery Market is divided into the following sub-markets based on technology, with yearly revenue for each part from 2015 to 2026 (historical and projected).

supervised learning, reinforcement learning, unsupervised learning, deep learning, and other technologies

The worldwide market is divided into the following sub-markets based on medication type, with yearly revenue for each part from 2015 to 2026 (historical and projected).

Large-molecule medications
• Drugs with small molecules

The worldwide Artificial Intelligence (AI) in Drug Discovery Market is divided into the following sub-markets based on therapeutic area, with annual revenue for 2015–2026 (historical and projected) given in each sector.

Oncology, cardiovascular disease, metabolic diseases, neurodegenerative diseases, and other therapeutic areas

The worldwide market is divided into the following sub-markets based on application, with annual revenue for each part from 2015 to 2026 (historical and projected).

Clinical Trials, Drug Design, Drug Evaluation, Information & Data Analysis, and Other Applications

The worldwide market is divided into the following sub-markets based on end user, with yearly revenue for each part from 2015 to 2026 (historical and projected).

• Academic & Research Institutes; Pharmaceutical & Biotechnology Companies; Contract Research Organizations

Along with the above national/local markets, the following geographic areas are thoroughly investigated:

• APAC (Japan, China, South Korea, Australia, India, and Rest of APAC; Rest of APAC is further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, and Sri Lanka)
In Europe (Germany, UK, France, Spain, Italy, Russia, Rest of Europe; Rest of Europe is further segmented into Belgium, Denmark, Austria, Norway, Sweden, The Netherlands, Poland, Czech Republic, Slovakia, Hungary, and Romania)
• America, North (U.S., Canada, and Mexico)
Latin America (Brazil, Chile, Argentina, Rest of South America)
• RoW (Saudi Arabia, UAE, Egypt)

There are thorough analyses and statistics for yearly revenue for each of the aforementioned areas and nations for the period of 2015 to 2026. All regional markets are broken down by country, and major national markets are divided by technology, therapeutic area, and end user during the course of the projection years.

The study also analyses the present competition landscape, the anticipated trend, and it provides profiles of major suppliers, including both established market leaders and significant up-and-coming companies.

Through AMR’s Risk Assessment System, possible risks related to investing in the worldwide AI in drug development industry are specifically assessed quantitatively and qualitatively. Critical Success Factors (CSFs) are developed based on the risk analysis and assessment as a guide to assist investors and shareholders in identifying new possibilities, managing and minimising risks, developing suitable business models, and making informed strategies and choices.

Artificial Intelligence (AI) in Drug Discovery Market: Key Players 

Atomwise, Inc. Berg LLC BenevolentAI
Cloud Pharmaceuticals, Inc. Cyclica Bioage Bioage
Envisagenics Deep Genomics
Exscientia
IBM Corporation, Google, Insilico Health
Corporation Microsoft Numedii, Inc.
Numerate
Inc. NVIDIA Corporation Owkin
Verge Genomics Xtalpi, Inc. Twoxar, Inc.